Seqirus UK Limited

Address: The Point, 29 Market Street

Sponsor Overview

assignment

Specializations

Influenza Prevention in Older Adults

Research activity is centered on influenza virus prevention in adults aged 50 years and older, with particular attention to people ≥65 years and those with stable comorbidities that increase the risk of complications from influenza infection.

Seasonal influenza vaccination
Older adult immunization
Risk reduction in medically vulnerable populations

The sponsor’s work in this area reflects a focus on protecting populations most affected by influenza-related illness and complications.

Adjuvanted and Quadrivalent Vaccine Development

Clinical research includes evaluation of adjuvanted influenza vaccines and quadrivalent vaccine formulations designed to broaden strain coverage and support immune response in older adults.

Fluad
Fluad Quadrivalent
High-dose influenza vaccine

These studies are directed toward influenza vaccine options tailored to age-related immune needs.

Immunogenicity and Serological Response

The sponsor investigates immune responses to influenza vaccination through hemagglutination inhibition measures, geometric mean titers, and seroconversion outcomes across vaccine strains.

Strain-specific antibody response
Cell-derived target viruses
Comparative immunogenicity

This area of work is focused on understanding how different influenza vaccine formulations stimulate protective immune activity.

Vaccine Safety and Tolerability

Trial activity also covers the safety and tolerability of influenza vaccines in large adult populations, including those with underlying health conditions that may affect vaccination outcomes.

Adult vaccine safety
Post-vaccination tolerability
Influenza immunisation in comorbid populations

This therapeutic focus supports the assessment of influenza vaccine use in routine preventive care for older and higher-risk individuals.

Trial Name	Country	Status
Efficacy and Safety Evaluation of MF59-Adjuvanted Influenza Vaccine Versus Non-Adjuvanted Vaccine in Adults Aged 65 and Older	Belgium Bulgaria Czechia Finland Italy Lithuania Poland Romania Spain The Netherlands	Not Recruiting
Phase 3 Study on Immunogenicity and Safety of High-Dose MF59-Adjuvanted Quadrivalent Influenza Vaccine in Adults Aged 50+ with Stable Comorbidities	Denmark Estonia Germany	Not Recruiting